Company intelligence / Profile preview

Albutec

Rostock, Mecklenburg-Vorpommern, Germany

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Albutec has completed clinical validation wherein their CE-marked liver support technology (Hepalbin-Cluster12, MaxiCycler) showed significant improvement in survival and recovery rates for patients with liver failure. Thousands of successful treatments have been performed in Europe, and enhanced technology recently reached broader commercialization.

Therapeutic areas: Gastroenterology
Modalities: DeviceNanoparticleBiologic
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Albutec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Albutec.

Explore the full profile